- Home
- ECX vs PHAT Comparison
ECX vs PHAT Comparison
Compare ECX & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECX
- PHAT
- Stock Information
- Founded
- ECX 2017
- PHAT 2018
- Country
- ECX China
- PHAT United States
- Employees
- ECX N/A
- PHAT N/A
- Industry
- ECX EDP Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- ECX Technology
- PHAT Health Care
- Exchange
- ECX Nasdaq
- PHAT Nasdaq
- Market Cap
- ECX 674.7M
- PHAT 769.0M
- IPO Year
- ECX N/A
- PHAT 2019
- Fundamental
- Price
- ECX $2.30
- PHAT $13.59
- Analyst Decision
- ECX Strong Buy
- PHAT Strong Buy
- Analyst Count
- ECX 1
- PHAT 5
- Target Price
- ECX $3.20
- PHAT $16.40
- AVG Volume (30 Days)
- ECX 2.6M
- PHAT 1.3M
- Earning Date
- ECX 11-03-2025
- PHAT 10-30-2025
- Dividend Yield
- ECX N/A
- PHAT N/A
- EPS Growth
- ECX N/A
- PHAT N/A
- EPS
- ECX N/A
- PHAT N/A
- Revenue
- ECX $756,543,682.00
- PHAT $114,039,000.00
- Revenue This Year
- ECX $817.95
- PHAT $213.11
- Revenue Next Year
- ECX $29.45
- PHAT $91.84
- P/E Ratio
- ECX N/A
- PHAT N/A
- Revenue Growth
- ECX 3.49
- PHAT 1049.82
- 52 Week Low
- ECX $0.76
- PHAT $2.21
- 52 Week High
- ECX $3.25
- PHAT $19.50
- Technical
- Relative Strength Index (RSI)
- ECX 57.72
- PHAT 59.76
- Support Level
- ECX $1.98
- PHAT $13.13
- Resistance Level
- ECX $2.48
- PHAT $14.30
- Average True Range (ATR)
- ECX 0.19
- PHAT 0.99
- MACD
- ECX -0.00
- PHAT 0.11
- Stochastic Oscillator
- ECX 67.00
- PHAT 78.58
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.